Focused ultrasound for immuno-adjuvant treatment of pancreatic cancer: An emerging clinical paradigm in the era of personalized oncotherapy

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67(1):7–30.
   PubMed Web of Science ®Google Scholar
• Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74(11):2913–2921.
   PubMed Web of Science ®Google Scholar
• DuFort CC, DelGiorno KE, Carlson MA, et al. Interstitial pressure in pancreatic ductal adenocarcinoma is dominated by a Gel-Fluid Phase. Biophys J 2016;110(9):2106–2119.
   PubMed Web of Science ®Google Scholar
• Hingorani SR, Harris WP, Beck JT, et al. Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer. Clin Cancer Res 2016;22(12):2848–2854.
   PubMed Web of Science ®Google Scholar
• Provenzano PP, Cuevas C, Chang AE, et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012;21(3):418–429.
   PubMed Web of Science ®Google Scholar
• Jacobetz MA, Chan DS, Neesse A, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2013;62(1):112–120.
   PubMed Web of Science ®Google Scholar
• Tamburrino A, Piro G, Carbone C, et al. Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy. Front Pharmacol 2013;4:56.
   PubMed Web of Science ®Google Scholar
• Bayne LJ, Beatty GL, Jhala N, et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 2012;21(6):822–835.
   PubMed Web of Science ®Google Scholar
• Clark CE, Hingorani SR, Mick R, et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007;67(19):9518–9527.
   PubMed Web of Science ®Google Scholar
• Balar AV, Weber JS. PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother 2017.
   Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366(26):2455–2465.
   PubMed Web of Science ®Google Scholar
• Nagaraj S, Youn JI, Weber H, et al. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res 2010;16(6):1812–1823.
   PubMed Web of Science ®Google Scholar
• Sanford DE, Porembka MR, Panni RZ, et al. A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma. J Cancer Ther 2013;4(3):797–803.
   PubMedGoogle Scholar
• Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010;33(8):828–833.
   PubMed Web of Science ®Google Scholar
• Le DT, Lutz E, Uram JN, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 2013;36(7):382–389.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011;331(6024):1612–1616.
   PubMed Web of Science ®Google Scholar
• Shibuya KC, Goel VK, Xiong W, et al. Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment. PLoS One 2014;9(5):e96565.
   PubMed Web of Science ®Google Scholar
• Ryschich E, Notzel T, Hinz U, et al. Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma. Clin Cancer Res 2005;11(2 Pt 1):498–504.
   PubMed Web of Science ®Google Scholar
• Pylayeva-Gupta Y, Lee KE, Hajdu CH, et al. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 2012;21(6):836–847.
   PubMed Web of Science ®Google Scholar
• Schmitz-Winnenthal FH, Volk C, Z'Graggen K, et al. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res 2005;65(21):10079–10087.
   PubMed Web of Science ®Google Scholar
• Feig C, Jones JO, Kraman M, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A 2013;110(50):20212–20217.
   PubMed Web of Science ®Google Scholar
• Stromnes IM, Brockenbrough JS, Izeradjene K, et al. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut 2014;63(11):1769–81.
   PubMed Web of Science ®Google Scholar
• Stromnes IM, Schmitt TM, Hulbert A, et al. T cells engineered against a native antigen can surmount immunologic and physical barriers to treat pancreatic ductal adenocarcinoma. Cancer Cell 2015;28(5):638–652.
   PubMed Web of Science ®Google Scholar
• Laheru D, Jaffee EM. Immunotherapy for pancreatic cancer – science driving clinical progress. Nat Rev Cancer 2005;5(6):459–467.
   PubMed Web of Science ®Google Scholar
• Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467(7319):1114–1117.
   PubMed Web of Science ®Google Scholar
• Zhou W, Capello M, Fredolini C, et al. Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells. J Proteome Res 2012;11(2):554–563.
   PubMed Web of Science ®Google Scholar
• Son J, Lyssiotis CA, Ying H, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 2013;496(7443):101–105.
   PubMed Web of Science ®Google Scholar
• Ying H, Kimmelman AC, Lyssiotis CA, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012;149(3):656–670.
   PubMed Web of Science ®Google Scholar
• Chang Q, Jurisica I, Do T, et al. Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer. Cancer Res 2011;71(8):3110–3120.
   PubMed Web of Science ®Google Scholar
• Hiraoka N, Ino Y, Sekine S, et al. Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation. Br J Cancer 2010;103(7):1057–1065.
   PubMed Web of Science ®Google Scholar
• Reiser-Erkan C, Erkan M, Pan Z, et al. Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer Biol Ther 2008;7(9):1352–1359.
   PubMed Web of Science ®Google Scholar
• Erkan M, Reiser-Erkan C, Michalski CW, et al. Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia 2009;11(5):497–508.
   PubMed Web of Science ®Google Scholar
• Lutz ER, Wu AA, Bigelow E, et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res 2014;2(7):616–631.
   PubMed Web of Science ®Google Scholar
• Hashimoto O, Shimizu K, Semba S, et al. Hypoxia induces tumor aggressiveness and the expansion of CD133-positive cells in a hypoxia-inducible factor-1alpha-dependent manner in pancreatic cancer cells. Pathobiology 2011;78(4):181–192.
   PubMed Web of Science ®Google Scholar
• Lu Y, Hu J, Sun W, et al. Hypoxia-mediated immune evasion of pancreatic carcinoma cells. Mol Med Rep 2015;11(5):3666–3672.
   PubMed Web of Science ®Google Scholar
• Schwartz DL, Powis G, Thitai-Kumar A, et al. The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther 2009;8(4):947–958.
   PubMed Web of Science ®Google Scholar
• Noman MZ, Hasmim M, Messai Y, et al. Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia. Am J Physiol Cell Physiol 2015;309(9):C569–579.
   PubMed Web of Science ®Google Scholar
• Barsoum IB, Smallwood CA, Siemens DR, et al. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res 2014;74(3):665–674.
   PubMed Web of Science ®Google Scholar
• Noman MZ, Desantis G, Janji B, et al. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 2014;211(5):781–790.
   PubMed Web of Science ®Google Scholar
• Caldwell CC, Kojima H, Lukashev D, et al. Differential effects of physiologically relevant hypoxic conditions on T lymphocyte development and effector functions. J Immunol. 2001;167(11):6140–6149.
   PubMed Web of Science ®Google Scholar
• Lukashev D, Klebanov B, Kojima H, et al. Cutting edge: hypoxia-inducible factor 1alpha and its activation-inducible short isoform I.1 negatively regulate functions of CD4+ and CD8+ T lymphocytes. J Immunol 2006;177(8):4962–4965.
   PubMed Web of Science ®Google Scholar
• Thiel M, Chouker A, Ohta A, et al. Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. PLoS Biol 2005;3(6):e174.
   PubMed Web of Science ®Google Scholar
• Thiel M, Caldwell CC, Kreth S, et al. Targeted deletion of HIF-1alpha gene in T cells prevents their inhibition in hypoxic inflamed tissues and improves septic mice survival. PLoS One 2007;2(9):e853.
   PubMed Web of Science ®Google Scholar
• Lardner A. The effects of extracellular pH on immune function. J Leukoc Biol 2001;69(4):522–530.
   PubMed Web of Science ®Google Scholar
• Nakagawa Y, Negishi Y, Shimizu M, et al. Effects of extracellular pH and hypoxia on the function and development of antigen-specific cytotoxic T lymphocytes. Immunol Lett 2015;167(2):72–86.
   PubMed Web of Science ®Google Scholar
• Redegeld F, Filippini A, Sitkovsky M. Comparative studies of the cytotoxic T lymphocyte-mediated cytotoxicity and of extracellular ATP-induced cell lysis. Different requirements in extracellular Mg2+ and pH. J Immunol 1991;147(10):3638–3645.
   Google Scholar
• Couvelard A, O'Toole D, Leek R, et al. Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas. Histopathology. 2005;46(6):668–676.
   PubMed Web of Science ®Google Scholar
• Couvelard A, O'Toole D, Turley H, et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer 2005;92(1):94–101.
   PubMed Web of Science ®Google Scholar
• Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1(3):313–323.
   PubMed Web of Science ®Google Scholar
• Zhu H, Wang D, Liu Y, et al. Role of the Hypoxia-inducible factor-1 alpha induced autophagy in the conversion of non-stem pancreatic cancer cells into CD133+ pancreatic cancer stem-like cells. Cancer Cell Int 2013;13(1):119.
   PubMed Web of Science ®Google Scholar
• Zhu H, Wang D, Zhang L, et al. Upregulation of autophagy by hypoxia-inducible factor-1alpha promotes EMT and metastatic ability of CD133+ pancreatic cancer stem-like cells during intermittent hypoxia. Oncol Rep 2014;32(3):935–942.
   PubMed Web of Science ®Google Scholar
• Maeda K, Ding Q, Yoshimitsu M, et al. CD133 modulate HIF-1alpha expression under hypoxia in EMT phenotype pancreatic cancer stem-like cells. Int J Mol Sci 2016;17(7).
   Web of Science ®Google Scholar
• Yuen A, Diaz B. The impact of hypoxia in pancreatic cancer invasion and metastasis. Hypoxia (Auckl) 2014;2:91–106.
   PubMedGoogle Scholar
• McEwan C, Kamila S, Owen J, et al. Combined sonodynamic and antimetabolite therapy for the improved treatment of pancreatic cancer using oxygen loaded microbubbles as a delivery vehicle. Biomaterials 2016;80:20–32.
   PubMed Web of Science ®Google Scholar
• McEwan C, Owen J, Stride E, et al. Oxygen carrying microbubbles for enhanced sonodynamic therapy of hypoxic tumours. J Control Release 2015;203:51–56.
   PubMed Web of Science ®Google Scholar
• Tang Y, Xu X, Guo S, et al. An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma. PLoS One 2014;9(3):e91551.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Yanagimoto H, Satoi S, et al. Circulating CD4 + CD25+ regulatory T cells in patients with pancreatic cancer. Pancreas 2012;41(3):409–415.
   PubMed Web of Science ®Google Scholar
• Hiraoka N, Onozato K, Kosuge T, et al. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006;12(18):5423–5434.
   PubMed Web of Science ®Google Scholar
• Yu F, Sharma S, Edwards J, et al. Dynamic expression of transcription factors T-bet and GATA-3 by regulatory T cells maintains immunotolerance. Nat Immunol 2015;16(2):197–206.
   PubMed Web of Science ®Google Scholar
• Chellappa S, Hugenschmidt H, Hagness M, et al. Regulatory T cells that co-express RORgammat and FOXP3 are pro-inflammatory and immunosuppressive and expand in human pancreatic cancer. Oncoimmunology 2016;5(4):e1102828.
   PubMed Web of Science ®Google Scholar
• Wohlfert EA, Grainger JR, Bouladoux N, et al. GATA3 controls Foxp3(+) regulatory T cell fate during inflammation in mice. J Clin Invest 2011;121(11):4503–4515.
   PubMed Web of Science ®Google Scholar
• Evans A, Costello E. The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion. Front Physiol 2012;3:270.
   PubMed Web of Science ®Google Scholar
• De Monte L, Reni M, Tassi E, et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 2011;208(3):469–478.
   PubMed Web of Science ®Google Scholar
• Tassi E, Gavazzi F, Albarello L, et al. Carcinoembryonic antigen-specific but not antiviral CD4+ T cell immunity is impaired in pancreatic carcinoma patients. J Immunol 2008;181(9):6595–6603.
   PubMed Web of Science ®Google Scholar
• Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004;4(8):583–594.
   PubMed Web of Science ®Google Scholar
• Wormann SM, Diakopoulos KN, Lesina M, et al. The immune network in pancreatic cancer development and progression. Oncogene 2014;33(23):2956–2967.
   PubMed Web of Science ®Google Scholar
• Winograd R, Byrne KT, Evans RA, et al. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. Cancer Immunol Res 2015;3(4):399–411.
   PubMed Web of Science ®Google Scholar
• Ozdemir BC, Pentcheva-Hoang T, Carstens JL, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 2014;25(6):719–734.
   PubMed Web of Science ®Google Scholar
• Rhim AD, Oberstein PE, Thomas DH, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 2014;25(6):735–747.
   PubMed Web of Science ®Google Scholar
• Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005;7(5):469–483.
   PubMed Web of Science ®Google Scholar
• Dimcevski G, Kotopoulis S, Bjanes T, et al. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. J Control Release 2016;243:172–181.
   PubMed Web of Science ®Google Scholar
• Tran E, Robbins PF, Rosenberg SA. ‘Final common pathway’ of human cancer immunotherapy: Targeting random somatic mutations. Nat Immunol 2017;18(3):255–262.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010;116(20):4099–4102.
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Riviere I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011;118(18):4817–4828.
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365(8):725–733.
   PubMed Web of Science ®Google Scholar
• Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015;385(9967):517–528.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015;33(6):540–549.
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Hanafi LA, Berger C, et al. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med 2016;8(355):355ra116.
   PubMed Web of Science ®Google Scholar
• Kawaoka T, Oka M, Takashima M, et al. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1. Oncol Rep 2008;20(1):155–163.
   PubMed Web of Science ®Google Scholar
• Posey AD, Jr., Schwab RD, Boesteanu AC, et al. Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity 2016;44(6):1444–1454.
   PubMed Web of Science ®Google Scholar
• Le DT, Wang-Gillam A, Picozzi V, et al. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol 2015;33(12):1325–1333.
   PubMed Web of Science ®Google Scholar
• Thomas AM, Santarsiero LM, Lutz ER, et al. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004;200(3):297–306.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute; National Institutes of Health Clinical Center. CAR T cell receptor immunotherapy targeting mesothelin for patients with metastatic cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 17.03.16]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01583686 NLM Identifier: NCT01583686.
   Google Scholar
• National Cancer Institute; National Institutes of Health Clinical Center. Immunotherapy using tumor infiltrating lymphocytes for patients with metastatic cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 17.03.16]. Available from: https://clinicaltrials.gov/show/NCT01174121 NLM Identifier: NCT01174121.
   Google Scholar
• Thind K, Padrnos LJ, Ramanathan RK, et al. Immunotherapy in pancreatic cancer treatment: a new frontier. Therap Adv Gastroenterol 2017;10(1):168–194.
   PubMed Web of Science ®Google Scholar
• Kotteas E, Saif MW, Syrigos K. Immunotherapy for pancreatic cancer. J Cancer Res Clin Oncol. 2016;142(8):1795–1805.
   PubMed Web of Science ®Google Scholar
• Lutz E, Yeo CJ, Lillemoe KD, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg 2011;253(2):328–335.
   PubMed Web of Science ®Google Scholar
• Laheru D, Lutz E, Burke J, et al. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 2008;14(5):1455–1463.
   PubMed Web of Science ®Google Scholar
• Le DT, Brockstedt DG, Nir-Paz R, et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res 2012;18(3):858–868.
   PubMed Web of Science ®Google Scholar
• Le DT, Ko AH, Wainberg ZA, et al. Results from a phase 2b, randomized, multicenter study of GVAX pan- creas and CRS-207 compared to chemotherapy in adults with previouslytreated metastatic pancreatic adeno- carcinoma (ECLIPSE Study). J Clin Oncol, 2017; 35(S4):345.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 –. Identifier NCT02243371, GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab; 2016 Aug 31 [cited 17.05.24]. Available from: https://clinicaltrials.gov/ct2/show/NCT02243371.
   Google Scholar
• Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499(7457):214–218.
   PubMed Web of Science ®Google Scholar
• Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012;491(7424):399–405.
   PubMed Web of Science ®Google Scholar
• Egawa K. Immuno-cell therapy of cancer in Japan. Anticancer Res 2004;24(5 C):3321–3326.
   PubMed Web of Science ®Google Scholar
• Protti MP, De Monte L. Immune infiltrates as predictive markers of survival in pancreatic cancer patients. Front Physiol 2013;4:210.
   PubMed Web of Science ®Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480(7378):480–489.
   PubMed Web of Science ®Google Scholar
• Chouaib S, Noman MZ, Kosmatopoulos K, et al. Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. Oncogene 2017;36(4):439–445.
   PubMed Web of Science ®Google Scholar
• Arina A, Karrison T, Galka E, et al. Transfer of allogeneic CD4+ T cells rescues CD8+ T cells in anti-PD-L1-resistant tumors leading to tumor eradication. Cancer Immunol Res 2017;5(2):127–136.
   PubMed Web of Science ®Google Scholar
• Luheshi NM, Coates-Ulrichsen J, Harper J, et al. Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model. Oncotarget 2016;7(14):18508–18520.
   PubMed Web of Science ®Google Scholar
• Chen J, Xiao-Zhong G, Qi XS. Clinical outcomes of specific immunotherapy in advanced pancreatic cancer: A systematic review and meta-analysis. J Immunol Res 2017;2017:8282391.
   PubMedGoogle Scholar
• Monjazeb AM, Hsiao HH, Sckisel GD, et al. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer. J Immunotoxicol 2012;9(3):248–258.
   PubMed Web of Science ®Google Scholar
• Frenkel V. Ultrasound mediated delivery of drugs and genes to solid tumors. Adv Drug Deliv Rev 2008;60(10):1193–1208.
   PubMed Web of Science ®Google Scholar
• Maloney E, Hwang JH. Emerging HIFU applications in cancer therapy. Int J Hyperthermia 2015;31(3):302–309.
   PubMed Web of Science ®Google Scholar
• Li PZ, Zhu SH, He W, et al. High-intensity focused ultrasound treatment for patients with unresectable pancreatic cancer. Hepatobiliary Pancreat Dis Int 2012;11(6):655–660.
   PubMed Web of Science ®Google Scholar
• Orsi F, Zhang L, Arnone P, et al. High-intensity focused ultrasound ablation: effective and safe therapy for solid tumors in difficult locations. AJR Am J Roentgenol 2010;195(3):W245–252.
   PubMed Web of Science ®Google Scholar
• Sung HY, Jung SE, Cho SH, et al. Long-term outcome of high-intensity focused ultrasound in advanced pancreatic cancer. Pancreas 2011;40(7):1080–1086.
   PubMed Web of Science ®Google Scholar
• Wang K, Chen Z, Meng Z, et al. Analgesic effect of high intensity focused ultrasound therapy for unresectable pancreatic cancer. Int J Hyperthermia 2011;27(2):101–107.
   PubMed Web of Science ®Google Scholar
• Xiong LL, Hwang JH, Huang XB, et al. Early clinical experience using high intensity focused ultrasound for palliation of inoperable pancreatic cancer. JOP 2009;10(2):123–129.
   PubMedGoogle Scholar
• Marinova M, Rauch M, Mucke M, et al. High-intensity focused ultrasound (HIFU) for pancreatic carcinoma: evaluation of feasibility, reduction of tumour volume and pain intensity. Eur Radiol 2016;26(11):4047–4056.
   PubMed Web of Science ®Google Scholar
• Zhao H, Yang G, Wang D, et al. Concurrent gemcitabine and high-intensity focused ultrasound therapy in patients with locally advanced pancreatic cancer. Anticancer Drugs 2010;21(4):447–452.
   PubMed Web of Science ®Google Scholar
• Dababou S, Marrocchio C, Rosenberg J, et al. A meta-analysis of palliative treatment of pancreatic cancer with high intensity focused ultrasound. J Ther Ultrasound 2017;5:9.
   PubMed Web of Science ®Google Scholar
• Ning ZY, Cheng CS, Xie J, et al. A retrospective analysis of survival factors of high intensity focused ultrasound (HIFU) treatment for unresectable pancreatic cancer. Discov Med 2016;21(118):435–445.
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhao F, Shi Y, et al. The efficacy of a new high intensity focused ultrasound therapy for locally advanced pancreatic cancer. J Cancer Res Clin Oncol 2017.
   Web of Science ®Google Scholar
• Li X, Wang K, Zheng L, et al. Retrospective analysis of high intensity focused ultrasound combined with S-1 in the treatment of metastatic pancreatic cancer after failure of gemcitabine. Am J Cancer Res 2016;6(1):84–90.
   PubMed Web of Science ®Google Scholar
• Lv W, Yan T, Wang G, et al. High-intensity focused ultrasound therapy in combination with gemcitabine for unresectable pancreatic carcinoma. Ther Clin Risk Manag 2016;12:687–6891.
   PubMed Web of Science ®Google Scholar
• Li CC, Wang YQ, Li YP, et al. High-intensity focused ultrasound for treatment of pancreatic cancer: a systematic review. J Evid Based Med 2014;7(4):270–281.
   PubMedGoogle Scholar
• Keane MG, Bramis K, Pereira SP, et al. Systematic review of novel ablative methods in locally advanced pancreatic cancer. World J Gastroenterol 2014;20(9):2267–2278.
   PubMed Web of Science ®Google Scholar
• Rombouts SJ, Vogel JA, van Santvoort HC, et al. Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer. Br J Surg 2015;102(3):182–193.
   PubMed Web of Science ®Google Scholar
• Wang X, Sun J. High-intensity focused ultrasound in patients with late-stage pancreatic carcinoma. Chin Med J (Engl) 2002;115(9):1332–1335.
   PubMed Web of Science ®Google Scholar
• Zhou Y. High-intensity focused ultrasound treatment for advanced pancreatic cancer. Gastroenterol Res Pract 2014;2014:205325.
   PubMedGoogle Scholar
• Hu Z, Yang XY, Liu Y, et al. Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCs. Biochem Biophys Res Commun 2005;335(1):124–131.
   PubMed Web of Science ®Google Scholar
• Hundt W, O'Connell-Rodwell CE, Bednarski MD, et al. In vitro effect of focused ultrasound or thermal stress on HSP70 expression and cell viability in three tumor cell lines. Acad Radiol 2007;14(7):859–870.
   PubMed Web of Science ®Google Scholar
• Hundt W, Steinbach S, Burbelko M, et al. Induction of luciferase activity under the control of an hsp70 promoter using high-intensity focused ultrasound: combination of bioluminescence and MRI imaging in three different tumour models. Technol Cancer Res Treat 2011;10(2):197–210.
   PubMed Web of Science ®Google Scholar
• Pockley AG. Heat shock proteins as regulators of the immune response. Lancet 2003;362(9382):469–476.
   PubMed Web of Science ®Google Scholar
• Wang X, Ji J, Zhang H, et al. Stimulation of dendritic cells by DAMPs in ALA-PDT treated SCC tumor cells. Oncotarget 2015;6(42):44688–44702.
   PubMed Web of Science ®Google Scholar
• Todryk SM, Gough MJ, Pockley AG. Facets of heat shock protein 70 show immunotherapeutic potential. Immunology 2003;110(1):1–9.
   PubMed Web of Science ®Google Scholar
• Bajzert J, Stefaniak T. [Heat shock protein HSP60 and the perspective for future using as vaccine antigens]. Postepy Hig Med Dosw (Online) 2015;69:1149–1168.
   PubMedGoogle Scholar
• Ter Haar G, Mouratidis P, Repasky E. Definition of basic properties of physical immunotherapy in pancreatic cancer using HIFU and immune checkpoint inhibition. 5th International Symposium on Focused Ultrasound; 30 August 2016; North Bethesda, MD. Unpublished results. Available from: https://www.cbi.nlm.nih.gov/pmc/articles/PMC5123388/pdf/40349_2016_Article_76.pdf [accessed 17.05.06].
   Google Scholar
• Orsi F, Bonomo G, Della Vigna P, et al. The “abscopal” effect after USgHIFU treatment of advanced pancreatic cancer. 5th International Symposium on Focused Ultrasound; 30 August 2016; North Bethesda, MD. Unpublished results. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5123388/pdf/40349_2016_Article_76.pdf [accessed 17.05.06].
   Google Scholar
• Ungaro A, Orsi F, Casadio C, et al. Successful palliative approach with high-intensity focused ultrasound in a patient with metastatic anaplastic pancreatic carcinoma: a case report. Ecancermedicalscience 2016;10:635.
   PubMed Web of Science ®Google Scholar
• Dimitrov D, Andreev T, Feradova H, et al. Multimodality treatment by FOLFOX plus HIFU in a case of advanced pancreatic carcinoma. A case report. JOP 2015;16(1):66–69.
   PubMed Web of Science ®Google Scholar
• Lee JY, Choi BI, Ryu JK, et al. Concurrent chemotherapy and pulsed high-intensity focused ultrasound therapy for the treatment of unresectable pancreatic cancer: initial experiences. Korean J Radiol 2011;12(2):176–186.
   PubMed Web of Science ®Google Scholar
• Lee ES, Lee JY, Kim H, et al. Pulsed high-intensity focused ultrasound enhances apoptosis of pancreatic cancer xenograft with gemcitabine. Ultrasound Med Biol 2013;39(11):1991–2000.
   PubMed Web of Science ®Google Scholar
• Li T, Chen H, Khokhlova T, et al. Passive cavitation detection during pulsed HIFU exposures of ex vivo tissues and in vivo mouse pancreatic tumors. Ultrasound Med Biol 2014;40(7):1523–1534.
   PubMed Web of Science ®Google Scholar
• Li T, Wang YN, Khokhlova TD, et al. Pulsed high-intensity focused ultrasound enhances delivery of doxorubicin in a preclinical model of pancreatic cancer. Cancer Res 2015;75(18):3738–3746.
   PubMed Web of Science ®Google Scholar
• Yu MH, Lee JY, Kim HR, et al. Therapeutic effects of microbubbles added to combined high-intensity focused ultrasound and chemotherapy in a pancreatic cancer xenograft model. Korean J Radiol 2016;17(5):779–788.
   PubMed Web of Science ®Google Scholar
• Burks SR, Ziadloo A, Hancock HA, et al. Investigation of cellular and molecular responses to pulsed focused ultrasound in a mouse model. PLoS One 2011;6(9):e24730.
   PubMed Web of Science ®Google Scholar
• Kramer G, Steiner GE, Grobl M, et al. Response to sublethal heat treatment of prostatic tumor cells and of prostatic tumor infiltrating T-cells. Prostate 2004;58(2):109–120.
   PubMed Web of Science ®Google Scholar
• Liu HL, Hsieh HY, Lu LA, et al. Low-pressure pulsed focused ultrasound with microbubbles promotes an anticancer immunological response. J Transl Med 2012;10:221.
   PubMed Web of Science ®Google Scholar
• Skalina K, Guha C. Stress response of cancer cells after low intensity focused ultrasound. 5th International Symposium on Focused Ultrasound; 30 August 2016; North Bethesda, MD. Unpublished results. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5123388/pdf/40349_2016_Article_76.pdf [accessed 17.05.06].
   Google Scholar
• Tebebi PA, Burks SR, Kim SJ, et al. Cyclooxygenase-2 or tumor necrosis factor-alpha inhibitors attenuate the mechanotransductive effects of pulsed focused ultrasound to suppress mesenchymal stromal cell homing to healthy and dystrophic muscle. Stem Cells 2015;33(4):1173–1186.
   PubMed Web of Science ®Google Scholar
• Aicher A, Heeschen C, Sasaki K, et al. Low-energy shock wave for enhancing recruitment of endothelial progenitor cells: a new modality to increase efficacy of cell therapy in chronic hind limb ischemia. Circulation 2006;114(25):2823–2830.
   PubMed Web of Science ®Google Scholar
• Burks SR, Ziadloo A, Kim SJ, et al. Noninvasive pulsed focused ultrasound allows spatiotemporal control of targeted homing for multiple stem cell types in murine skeletal muscle and the magnitude of cell homing can be increased through repeated applications. Stem Cells 2013;31(11):2551–2560.
   PubMed Web of Science ®Google Scholar
• Simon JC, Sapozhnikov OA, Khokhlova VA, et al. Ultrasonic atomization of tissue and its role in tissue fractionation by high intensity focused ultrasound. Phys Med Biol 2012;57(23):8061–8078.
   PubMed Web of Science ®Google Scholar
• Wang YN, Khokhlova T, Bailey M, et al. Histological and biochemical analysis of mechanical and thermal bioeffects in boiling histotripsy lesions induced by high intensity focused ultrasound. Ultrasound Med Biol 2013;39(3):424–438.
   PubMed Web of Science ®Google Scholar
• Canney MS, Khokhlova VA, Bessonova OV, et al. Shock-induced heating and millisecond boiling in gels and tissue due to high intensity focused ultrasound. Ultrasound Med Biol 2010;36(2):250–267.
   PubMed Web of Science ®Google Scholar
• Khokhlova TD, Canney MS, Khokhlova VA, et al. Controlled tissue emulsification produced by high intensity focused ultrasound shock waves and millisecond boiling. J Acoust Soc Am 2011;130(5):3498–510.
   PubMed Web of Science ®Google Scholar
• Xu Z, Fowlkes JB, Rothman ED, et al. Controlled ultrasound tissue erosion: the role of dynamic interaction between insonation and microbubble activity. J Acoust Soc Am 2005;117(1):424–435.
   PubMed Web of Science ®Google Scholar
• Maxwell AD, Wang TY, Cain CA, et al. Cavitation clouds created by shock scattering from bubbles during histotripsy. J Acoust Soc Am 2011;130(4):1888–1898.
   PubMed Web of Science ®Google Scholar
• Schade GR, Wang YN, S'Andrea S, et al. Initial assessment of boiling histotripsy ablation of renal cell carcinoma in the Eker rat. International Society of Therapeutic Ultrasound; 18 April 2015; Utrecht, Netherlands. Unpublished results. Available from: http://www.istu.org/events/ann2015/abstractBook.pdf [accessed 17.05.06].
   Google Scholar
• Venereau E, Schiraldi M, Uguccioni M, et al. HMGB1 and leukocyte migration during trauma and sterile inflammation. Mol Immunol 2013;55(1):76–82.
   PubMed Web of Science ®Google Scholar
• Schade GR, Wang YN, Pillarisetty V, et al. Characterizing the immune response to boiling histotripsy ablation of renal carcinoma in the Eker rat. 5th International Symposium on Focused Ultrasound; 30 August 2016; North Bethesda, MD. Unpublished results. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5123388/pdf/40349_2016_Article_76.pdf [accessed 17.05.06].
   Google Scholar
• Yee C, Lizee G, Schueneman AJ. Endogenous T-cell therapy: Clinical experience. Cancer J 2015;21(6):492–500.
   PubMed Web of Science ®Google Scholar
• Xia JZ, Xie FL, Ran LF, et al. High-intensity focused ultrasound tumor ablation activates autologous tumor-specific cytotoxic T lymphocytes. Ultrasound Med Biol 2012;38(8):1363–1371.
   PubMed Web of Science ®Google Scholar
• Ran LF, Xie XP, Xia JZ, et al. Specific antitumour immunity of HIFU-activated cytotoxic T lymphocytes after adoptive transfusion in tumour-bearing mice. Int J Hyperthermia 2016;32(2):204–210.
   PubMed Web of Science ®Google Scholar
• Xing Y, Lu X, Pua EC, et al. The effect of high intensity focused ultrasound treatment on metastases in a murine melanoma model. Biochem Biophys Res Commun 2008;375(4):645–650.
   PubMed Web of Science ®Google Scholar
• Hu Z, Yang XY, Liu Y, et al. Investigation of HIFU-induced anti-tumor immunity in a murine tumor model. J Transl Med 2007;5:34.
   PubMed Web of Science ®Google Scholar
• Chevillet JR, Khokhlova TD, Giraldez MD, et al. Release of Cell-free MicroRNA tumor biomarkers into the blood circulation with pulsed focused ultrasound: A noninvasive, anatomically localized, molecular liquid biopsy. Radiology 2017;283(1):158–167.
   PubMed Web of Science ®Google Scholar
• Khokhlova VA, Fowlkes JB, Roberts WW, et al. Histotripsy methods in mechanical disintegration of tissue: towards clinical applications. Int J Hyperthermia 2015;31(2):145–162.
   PubMed Web of Science ®Google Scholar
• Khokhlova TD, Wang YN, Simon JC, et al. Ultrasound-guided tissue fractionation by high intensity focused ultrasound in an in vivo porcine liver model. Proc Natl Acad Sci U S A 2014;111(22):8161–8166.
   PubMed Web of Science ®Google Scholar
• Huang X, Yuan F, Liang M, et al. M-HIFU inhibits tumor growth, suppresses STAT3 activity and enhances tumor specific immunity in a transplant tumor model of prostate cancer. PLoS One 2012;7(7):e41632.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Deng J, Feng J, et al. Enhancement of antitumor vaccine in ablated hepatocellular carcinoma by high-intensity focused ultrasound. World J Gastroenterol 2010;16(28):3584–3591.
   PubMed Web of Science ®Google Scholar
• Unga J, Hashida M. Ultrasound induced cancer immunotherapy. Adv Drug Deliv Rev 2014;72:144–153.
   PubMed Web of Science ®Google Scholar
• Sakakima Y, Hayashi S, Yagi Y, et al. Gene therapy for hepatocellular carcinoma using sonoporation enhanced by contrast agents. Cancer Gene Ther 2005;12(11):884–889.
   PubMed Web of Science ®Google Scholar
• Zolochevska O, Xia X, Williams BJ, et al. Sonoporation delivery of interleukin-27 gene therapy efficiently reduces prostate tumor cell growth in vivo. Hum Gene Ther 2011;22(12):1537–1550.
   PubMed Web of Science ®Google Scholar
• Suzuki R, Oda Y, Utoguchi N, et al. A novel strategy utilizing ultrasound for antigen delivery in dendritic cell-based cancer immunotherapy. J Control Release 2009;133(3):198–205.
   PubMed Web of Science ®Google Scholar
• Oda Y, Suzuki R, Otake S, Nishiie N, et al. Prophylactic immunization with Bubble liposomes and ultrasound-treated dendritic cells provided a four-fold decrease in the frequency of melanoma lung metastasis. J Control Release 2012;160(2):362–326.
   PubMed Web of Science ®Google Scholar
• Suzuki R, Namai E, Oda Y, et al. Cancer gene therapy by IL-12 gene delivery using liposomal bubbles and tumoral ultrasound exposure. J Control Release 2010;142(2):245–250.
   PubMed Web of Science ®Google Scholar
• Un K, Kawakami S, Suzuki R, et al. Suppression of melanoma growth and metastasis by DNA vaccination using an ultrasound-responsive and mannose-modified gene carrier. Mol Pharm 2011;8(2):543–54.
   PubMed Web of Science ®Google Scholar
• Un K, Kawakami S, Suzuki R, et al. Development of an ultrasound-responsive and mannose-modified gene carrier for DNA vaccine therapy. Biomaterials 2010;31(30):7813–7826.
   PubMed Web of Science ®Google Scholar